Penumbra Inc: insider trades · United States · SEC (Form 4)

About Penumbra Inc

Penumbra, Inc. (NYSE: PEN) is a United States-based medical device company headquartered in Alameda, California. Founded in 2004, Penumbra designs, develops, manufactures, and markets innovative products for high-acuity conditions with significant unmet medical need. For equity investors, the company sits squarely in the medtech growth bucket, with a business model built on proprietary technology, clinical adoption, and continued product innovation rather than on broad commodity device exposure. ([penumbrainc.com](https://www.penumbrainc.com/about-us/?utm_source=openai)) Penumbra’s core franchise is thrombectomy. The company’s portfolio includes the Penumbra System for neuro thrombectomy, the Indigo platform for peripheral thrombectomy, and the Lightning/CAVT (Computer Assisted Vacuum Thrombectomy) family, which is designed to remove clot from arteries and veins, including in pulmonary embolism and acute limb ischemia settings. Penumbra also sells peripheral embolization solutions such as the Ruby platform, broadening its exposure across interventional vascular care. In practice, the company’s product set is aimed at minimally invasive clot removal and embolization procedures where speed, precision, and procedural simplicity matter. ([penumbrainc.com](https://www.penumbrainc.com/products/penumbra-system/?utm_source=openai)) From a competitive standpoint, Penumbra is positioned as a leader in aspiration-based thrombectomy and computer-assisted clot removal. Its differentiation comes from a combination of device engineering, intelligent aspiration algorithms, and an expanding platform strategy that seeks to address arterial, venous, pulmonary, and mesenteric thrombus. The company has emphasized that its Lightning portfolio is among the most comprehensive mechanical thrombectomy product lines available in the U.S. market, which supports its premium positioning in a specialized segment of medtech. ([penumbrainc.com](https://www.penumbrainc.com/penumbra-expands-computer-aided-thrombectomy-offerings-with-lightning-bolt-7-technology-designed-to-rapidly-remove-blood-clots-with-modulated-aspiration/?utm_source=openai)) Geographically, Penumbra is anchored in the United States but operates internationally, including in Europe, where it continues to expand regulatory clearances and product launches. This matters because medtech growth is often driven by the intersection of clinical evidence, reimbursement pathways, and market access across multiple regions. Penumbra’s international footprint suggests a company that is not only U.S.-centric, but also pursuing broader adoption of its thrombectomy and embolization technologies. ([penumbrainc.com](https://www.penumbrainc.com/about-us/?utm_source=openai)) Recent company news has reinforced the investment case. In 2025 and 2026, Penumbra highlighted clinical readouts around STORM-PE and STRIKE-PE, which supported favorable functional and procedural outcomes in pulmonary embolism and venous thromboembolism. The company also launched Lightning Flash 3.0 and announced European additions such as ELEMENT and Select+, completing more of its VTE thrombectomy workflow. In January 2026, Penumbra also issued preliminary full-year 2025 financial results showing continued revenue growth, underscoring the operating momentum behind the business on the NYSE in the United States. ([penumbrainc.com](https://www.penumbrainc.com/investors/press-releases/?utm_source=openai))